Semaglutide ( Purity >98.0%)
Semaglutide is a potent peptide that activates GLP-1 receptors, supporting weight management, appetite regulation, blood glucose control, and overall metabolic function. By helping to curb cravings and extend the feeling of fullness after meals, it has gained significant interest among those aiming to lose fat and improve body composition. Administered once weekly and backed by clinical evidence, Semaglutide is commonly integrated into comprehensive wellness and weight-control programs.
Also known as: Ozempic, Wegovy, Rybelsus
• A GLP-1 receptor agonist with multiple FDA-approved uses, including weight management, type 2 diabetes (T2D), cardiovascular risk reduction, and kidney protection. The oral version, marketed as Wegovy, received FDA approval in December 2025, becoming the first oral GLP-1 treatment approved for weight loss.
• Status: FDA-approved. Evidence level: Supported by FDA approval.
• Typical dosage: Ranges from 1 to 2.4 mg once weekly following dose escalation. Administered either as a weekly subcutaneous injection or orally (as Rybelsus).
• Investigated for: Weight reduction, appetite regulation, and blood glucose control.
• Status: FDA-approved. Evidence level: Supported by FDA approval.
• Typical dosage: Ranges from 1 to 2.4 mg once weekly following dose escalation. Administered either as a weekly subcutaneous injection or orally (as Rybelsus).
• Investigated for: Weight reduction, appetite regulation, and blood glucose control.
Reviews
There are no reviews yet.